Effects on Motor and Nonmotor Symptoms of Parkinson's Disease

Large, multicenter, randomized controlled trials have demonstrated the safety and efficacy of rotigotine 24-hour transdermal system for the treatment of motor symptoms associated with both early and advanced Parkinson’s disease (PD). In addition to the significant improvements in motor function and reductions in off-time, nonmotor symptoms, such as sleep, mood, and quality of life, were significantly improved with rotigotine. Adverse events (AEs) were typical of those seen with other dopamine agonists, with the mostcommonAEsincludingapplicationsitereactions,nausea,dizziness,andsomnolence. Rotigotine transdermal system is a safe and efficacious treatment option in patients with early PD as monotherapy and as adjunct to levodopa in patients with more advanced PD.